Lion Point Capital, LP — 13F Holdings & Portfolio
CIK 1643354 · latest 13F-HR filed 2026-08-14
Lion Point Capital, LP manages $20.9M in 13F-reported U.S. long-equity assets across 35 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are CUE (7.99%), PRAX (7.13%), MLTX (6.29%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position and exited 1; 21 existing positions rose in reported value and 7 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 55%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Apr 30, 2026.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| CEDERHOLM, CARL, DIDRIC MARCUS Control | CHIEF INVESTMENT OFFICER since Aug 2014 | Less than 5% | Individual |
| FRANOV, ANA Control | CHIEF FINANCIAL OFFICER since Jan 2019 | Less than 5% | Individual |
| KARIM, IRSHAD, S Control | GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER since Sep 2015 | Less than 5% | Individual |
| LEJONUDDEN FAMILY LLC Control | LIMITED PARTNER since Apr 2015 | 75% or more | Domestic Entity |
| LION POINT HOLDINGS GP LLC Control | GENERAL PARTNER since Aug 2014 | Less than 5% | Domestic Entity |
| MURPHY, JAMES, DANIEL Control | CHIEF OPERATING OFFICER since Aug 2014 | Less than 5% | Individual |
| CEDERHOLM, CARL, DIDRIC MARCUS Control Indirect owner via LION POINT HOLDINGS GP LLC | MANAGER since Apr 2015 | General partner, trustee or manager | Individual |
| CEDERHOLM, CARL, DIDRIC MARCUS Control Indirect owner via LEJONUDDEN FAMILY LLC | MEMBER AND MANAGER since Mar 2015 | 75% or more | Individual |
| LEJONUDDEN FAMILY LLC Control Indirect owner via LION POINT HOLDINGS GP LLC | MEMBER since Apr 2015 | 75% or more | Domestic Entity |
Ownership & leadership changes · 5 filings with changes since Feb 13, 2015
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedCEDERHOLM, CARL, DIDRIC MARCUS · title CHIEF INVESTMENT OFFICER / LIMITED PARTNER → CHIEF INVESTMENT OFFICER; ownership 75% or more → Less than 5%
- No longer listedCONNERSVILLE LLC · MEMBER · 25–50% · indirect via LION POINT HOLDINGS GP LLC · control person · listed since Apr 2015
- No longer listedCONNERSVILLE LLC · LIMITED PARTNER · 10–25% · listed since Apr 2015
- No longer listedFREEMAN, JAMES, BENJAMIN · HEAD OF RESEARCH / LIMITED PARTNER · 25–50% · control person · listed since Aug 2014
- No longer listedFREEMAN, JAMES, BENJAMIN · MANAGER · General partner, trustee or manager · indirect via LION POINT HOLDINGS GP LLC · control person · listed since Apr 2015
- No longer listedFREEMAN, JAMES, BENJAMIN · MEMBER AND MANAGER · 75% or more · indirect via CONNERSVILLE LLC · control person · listed since Mar 2015
- ChangedLEJONUDDEN FAMILY LLC · ownership 50–75% → 75% or more
- AddedCEDERHOLM, CARL, DIDRIC MARCUS · MEMBER AND MANAGER · 75% or more · indirect via LEJONUDDEN FAMILY LLC · control person
- AddedCONNERSVILLE LLC · MEMBER · 25–50% · indirect via LION POINT HOLDINGS GP LLC · control person
- AddedCONNERSVILLE LLC · LIMITED PARTNER · 10–25%
- AddedFRANOV, ANA · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- AddedFREEMAN, JAMES, BENJAMIN · MEMBER AND MANAGER · 75% or more · indirect via CONNERSVILLE LLC · control person
- AddedLEJONUDDEN FAMILY LLC · MEMBER · 75% or more · indirect via LION POINT HOLDINGS GP LLC · control person
- AddedLEJONUDDEN FAMILY LLC · LIMITED PARTNER · 50–75% · control person
- ChangedCEDERHOLM, CARL, DIDRIC MARCUS · indirect via LION POINT HOLDINGS GP LLC: title MANAGING MEMBER → MANAGER; ownership 75% or more → General partner, trustee or manager
- ChangedFREEMAN, JAMES, BENJAMIN · indirect via LION POINT HOLDINGS GP LLC: title MANAGING MEMBER → MANAGER; ownership 25–50% → General partner, trustee or manager
- ChangedMURPHY, JAMES, DANIEL · title CHIEF FINANCIAL OFFICER / CHIEF OPERATING OFFICER → CHIEF OPERATING OFFICER
- ChangedKARIM, IRSHAD, S · title CHIEF COMPLIANCE OFFICER → GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER
- AddedKARIM, IRSHAD, S · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedMURPHY, JAMES, DANIEL · title CHIEF COMPLIANCE OFFICER / CHIEF FINANCIAL OFFICER / CHIEF OPERATING OFFICER → CHIEF FINANCIAL OFFICER / CHIEF OPERATING OFFICER
- ListedCEDERHOLM, CARL, DIDRIC MARCUS · CHIEF INVESTMENT OFFICER / LIMITED PARTNER · 75% or more · control person
- ListedCEDERHOLM, CARL, DIDRIC MARCUS · MANAGING MEMBER · 75% or more · indirect via LION POINT HOLDINGS GP LLC · control person
- ListedFREEMAN, JAMES, BENJAMIN · HEAD OF RESEARCH / LIMITED PARTNER · 25–50% · control person
- ListedFREEMAN, JAMES, BENJAMIN · MANAGING MEMBER · 25–50% · indirect via LION POINT HOLDINGS GP LLC · control person
- ListedLION POINT HOLDINGS GP LLC · GENERAL PARTNER · Less than 5% · control person
- ListedMURPHY, JAMES, DANIEL · CHIEF COMPLIANCE OFFICER / CHIEF FINANCIAL OFFICER / CHIEF OPERATING OFFICER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- COMPASS PATHWAYS PLC$689.6K +155.9%
- FENNEC PHARMACEUTICALS INC$517.2K +74.8%
- UNIQURE NV$436.7K +181.7%
- BIOHAVEN LTD$331.9K +75.9%
- LANTHEUS HLDGS INC$193.0K +46.3%
Top Trims
- JASPER THERAPEUTICS INC-$211.7K -52.0%
- GERON CORP-$121.4K -14.1%
- ARDELYX INC-$114.5K -14.9%
- SAREPTA THERAPEUTICS INC-$108.0K -17.4%
- SYNDAX PHARMACEUTICALS INC-$54.0K -6.4%
Lion Point Capital, LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CUE BIOPHARMA INC | CUE | 22978P205 | $1.7M | 7.99% | 52,928 | SH |
| 2 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $1.5M | 7.13% | 4,450 | SH |
| 3 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $1.3M | 6.29% | 67,500 | SH |
| 4 | FENNEC PHARMACEUTICALS INC | FENC | 31447P100 | $1.2M | 5.78% | 112,434 | SH |
| 5 | ROYALTY PHARMA PLC | RPRX | G7709Q104 | $1.2M | 5.74% | 21,400 | SH |
| 6 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $1.1M | 5.41% | 80,000 | SH |
| 7 | MILESTONE PHARMACEUTICALS IN | MIST | 59935V107 | $1.1M | 5.26% | 820,000 | SH |
| 8 | BENITEC BIOPHARMA INC | BNTC | 08205P209 | $829.6K | 3.97% | 62,000 | SH |
| 9 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $787.0K | 3.76% | 36,000 | SH |
| 10 | BIOHAVEN LTD | BHVN | G1110E107 | $769.3K | 3.68% | 51,700 | SH |
| 11 | GERON CORP | GERN | 374163103 | $739.8K | 3.54% | 578,000 | SH |
| 12 | UNIQURE NV | QURE | N90064101 | $677.1K | 3.24% | 14,700 | SH |
| 13 | ARDELYX INC | ARDX | 039697107 | $656.1K | 3.14% | 128,650 | SH |
| 14 | LANTHEUS HLDGS INC | LNTH | 516544103 | $610.2K | 2.92% | 5,500 | SH |
| 15 | DISC MEDICINE INC | IRON | 254604101 | $592.4K | 2.83% | 8,100 | SH |
| 16 | SAREPTA THERAPEUTICS INC | SRPT | 803607100 | $512.1K | 2.45% | 28,500 | SH |
| 17 | HUMACYTE INC | HUMA | 44486Q103 | $507.3K | 2.43% | 650,000 | SH |
| 18 | KURA ONCOLOGY INC | KURA | 50127T109 | $504.6K | 2.41% | 46,000 | SH |
| 19 | VIATRIS INC | VTRS | 92556V106 | $439.9K | 2.10% | 27,700 | SH |
| 20 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $399.8K | 1.91% | 18,000 | SH |
| 21 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $372.4K | 1.78% | 5,000 | SH |
| 22 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $369.7K | 1.77% | 9,100 | SH |
| 23 | PACIRA BIOSCIENCES INC | PCRX | 695127100 | $342.5K | 1.64% | 13,500 | SH |
| 24 | REGENXBIO INC | RGNX | 75901B107 | $318.7K | 1.52% | 26,600 | SH |
| 25 | ROCKET PHARMACEUTICALS INC | RCKT | 77313F106 | $294.1K | 1.41% | 86,000 | SH |
| 26 | JANUX THERAPEUTICS INC | JANX | 47103J105 | $291.8K | 1.40% | 19,000 | SH |
| 27 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $283.3K | 1.36% | 10,500 | SH |
| 28 | GH RESEARCH PLC | GHRS | G3855L106 | $274.2K | 1.31% | 10,200 | SH |
| 29 | SERES THERAPEUTICS INC | MCRB | 81750R201 | $249.1K | 1.19% | 31,570 | SH |
| 30 | AZENTA INC | AZTA | 114340102 | $247.5K | 1.18% | 9,700 | SH |
| 31 | JASPER THERAPEUTICS INC | JSPR | 471871202 | $195.8K | 0.94% | 465,000 | SH |
| 32 | INNOVIVA INC | INVA | 45781M101 | $186.2K | 0.89% | 8,200 | SH |
| 33 | INNATE PHARMA S A | IPHA | 45781K204 | $149.3K | 0.71% | 81,151 | SH |
| 34 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $137.7K | 0.66% | 5,250 | SH |
| 35 | SPRUCE BIOSCIENCES INC | SPRB | 85209E208 | $54.0K | 0.26% | 1,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $20.9M | 35 | 0001013594-26-000908 |
| 2026-03-31 | 2026-05-15 | $16.7M | 35 | 0001013594-26-000605 |
| 2025-12-31 | 2026-02-17 | $19.3M | 39 | 0001013594-26-000252 |
| 2025-09-30 | 2025-11-14 | $17.6M | 27 | 0001013594-25-001425 |
SUITE 2609
NEW YORK, NY 10152